Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005. by �꽌�씪 et al.
D I A B E T E S  &  M E T A B O L I S M  J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2012 Korean Diabetes Association http://e-dmj.org
Diabetes Metab J 2012;36:43-55
Prevalence of Dyslipidemia among Korean Adults: 
Korea National Health and Nutrition Survey 1998-2005
Myung Ha Lee1, Hyeon Chang Kim1,2, Song Vogue Ahn3, Nam Wook Hur1, Dong Phil Choi1, Chang Gyu Park4, Il Suh1
1Department of Preventive Medicine, 2Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, 
3Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, 
4Department of Cardiology, Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea
Background: Dyslipidemia is a disorder of lipid metabolism, including elevated total cholesterol, elevated triglyceride, elevated 
low density lipoprotein cholesterol (LDL-C), and decreased high density lipoprotein cholesterol (HDL-C). The objective of this 
study was to investigate recent changes in the prevalence of dyslipidemia and also the rates of awareness, treatment, and control 
of dyslipidemia among Korean adults.
Methods: Dyslipidemia is defined according to the National Cholesterol Education Program-Adult Treatment Panel III as total 
cholesterol ≥240 mg/dL, LDL-C ≥160 mg/dL, HDL-C <40 mg/dL, and triglyceride ≥200 mg/dL. The prevalence of dyslipid-
emia was estimated for adults aged ≥20 years using the Korea National Health and Nutrition Survey (KNHANES) in 1998 (n=
6,923), 2001 (n=4,882), and 2005 (n=5,323). Rates of awareness, treatment and control of dyslipidemia were calculated for adults 
aged ≥30 years using the KNHANES in 2005 (n=4,654).
Results: The prevalence of dyslipidemia (aged ≥20 years) increased from 32.4% in 1998 to 42.6% in 2001 and 44.1% in 2005. 
Compared with the KNHANES in 1998, the prevalence of dyslipidemia was 47% (95% confidence interval [CI], 35% to 59%) 
higher in 2001 and 61% (95% CI, 49% to 75%) higher in 2005. In 2005, only 9.5% of people with dyslipidemia were aware of the 
disease, 5.2% used lipid-lowering medication, and 33.2% of patients with treatment reached treatment goals.
Conclusion: The prevalence of dyslipidemia in Korea gradually increased between 1998 and 2005. These findings suggest that 
more intense efforts for the prevention and treatment of dyslipidemia may lead to further improvement in the management of 
dyslipidemia.
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INTRODUCTION
Dyslipidemia means abnormal amount of lipids in the blood 
and its clinically important types include elevated total choles-
terol, elevated triglycerides, elevated low density lipoprotein 
cholesterol (LDL-C), and decreased high density lipoprotein 
cholesterol (HDL-C) levels. Many previous studies have re-
ported that dyslipidemia increases the risk of cardiovascular 
diseases [1-3]. Due to its asymptomatic nature and slow pro-
gression, it is difficult for individuals to notice or manage it. 
According to the 30-year follow-up study, a 10 mg/dL increase 
in total cholesterol was associated with 5% increase of total 
mortality and 9% increase of cardiovascular mortality [4]. 
Coronary heart disease and cerebrovascular disease caused 
twelve million deaths per year worldwide [5]. In South Korea, 
cerebrovascular disease, cardiovascular disease, and other cir-
culatory diseases account for 20% of the total deaths and great 
disease burden as well [6,7]. However, there has not yet been a 
representative study that shows the prevalence of dyslipidemia 
in Korea. Thus we estimated the prevalence of dyslipidemia 
and its components among Korean adults based on the 1998, 
2001, and 2005 Korean National Health and Nutrition Exami-
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nation Survey (KNHANES) datasets. This study also investi-
gated the rates of awareness, treatment, and control of dyslip-
idemia among Korean adults. 
METHODS
This study is based on the data obtained from the KNHANES, 
which is a nationwide survey examining the general health and 
nutrition status of the Korean people [8]. It consisted of four 
distinct surveys: the health interview survey, the health behav-
ior survey, the health examination survey, and the nutrition 
survey. The KNHANES was conducted in 1998 (KNHANES 
I), 2001 (KNHANES II), and 2005 (KNHANES III). A strati-
fied, multistage probability sampling design was used in 
KNHANES, and 42,780 individuals from 600 districts were 
chosen in consideration of location and residence-type in or-
der to establish full representativeness of the whole nation. All 
600 sampling districts were subject to the health interview and 
behavior surveys, and 200 districts of them (one third random 
sample) were subject to the health examination and nutrition 
surveys.
 The diagnosis of dyslipidemia was based on the presence of 
one or more of the following criteria, according to the criteria 
of the National Cholesterol Education Program Adult Treat-
ment Panel III [9]. In the KNHANES I (year 1998) and II (year 
2001), individuals were not asked about their blood lipid levels 
and management in the health interview survey because dys-
lipidemia was assumed to be very low in Korea. Thus dyslipid-
emia was defined solely based on the blood test results in the 
health examination in 1998 and 2001. But in 2005, dyslipid-
emia was determined with fasting blood tests as well as health 
interview survey data. Blood samples were collected in the 
morning after fasting for at least 8 hours and analyzed in the 
certified central laboratory on the same day. Serum total cho-
lesterol, triglycerides, and HDL-C were measured by automat-
ed enzymatic techniques. LDL-C was calculated using the Frie-
dewald’s formula [10] in individuals with triglycerides <400 
mg/dL. Therefore the definitions of dyslipidemia are as follows: 
In 1998 and 2001, total cholesterol levels over 240 mg/dL in the 
blood test results were defined as hypercholesterolemia, HDL-
C levels under 40 mg/dL were defined as hypo-HDL-choles-
terolemia, and triglyceride levels over 200 mg/dL were defined 
as hypertriglycemia. LDL-C levels over 160 mg/dL were de-
fined as hyper-LDL-cholesterolemia. In 2005, hypo-HDL-
cholesterolemia and hypertriglycemia were defined in the 
same way as they were in 1998 and 2001. Hypercholesterol-
emia was defined as the following three cases: 1) a total choles-
terol level over 240 mg/dL from a blood test taken after fasting, 
or 2) the use of lipid-lowering drugs, or 3) when the subject 
has been diagnosed with dyslipidemia by a physician. Hyper-
LDL-cholesterolemia was defined as: 1) an LDL-C level over 
160 mg/dL, or 2) the use of lipid-lowering drugs, or 3) when 
the subject has been diagnosed with dyslipidemia by a physi-
cian (Table 1). The reason being, that despite the discrepancies 
in the definition of dyslipidemia by year, it is optimal for the 
definition to be accurate for each year. In the case of this study, 
the analysis was done excluding any measurements that were 
missing total cholesterol, HDL-C, or triglycerides. We ana-
lyzed subjects over 20 years old who participated in the health 
examination survey. 
 The awareness rate of dyslipidemia, physician diagnosis 
rate, treatment rate, and control rate were defined using the 
health interview survey and the health examination survey re-
sults from KNHANES III (2005) only. The awareness rate is 
Table 1. Definitions of dyslipidemia and related lipid profiles
KNHANES I (1998), II (2001) 
Health examination survey
KNHANES III (2005) Health examination survey  
& health interview survey
Hypercholesterolemia ≥240 mg/dL ≥240 mg/dL or those who were identified to be previously diagnosed with 
dyslipidemia or those who were treated with lipid-lowering drugs
Hypo-HDL-cholesterolemia <40 mg/dL <40 mg/dL
Hyper-LDL-cholesterolemia ≥160 mg/dL ≥160 mg/dL or those who were identified to be previously diagnosed with 
dyslipidemia or those who were treated with lipid-lowering drugs
Hypertriglycemia ≥200 mg/dL ≥ 200 mg/dL
Dyslipidemia At least one of the fasting lipid profile consists of hypercholesterolemia,  
hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, hypertriglycemia
KNHANES, Korea National Health and Nutrition Examination Survey; HDL, high density lipoprotein; LDL, low density lipoprotein.
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defined as the number of individuals whose response to the 
health interview survey indicated that they have had dyslipid-
emia in the past divided by the number of people with dyslip-
idemia, and the physician diagnosis rate is defined as the num-
ber of cases where individuals replied that they had been diag-
nosed by a physician out of those who are dyslipidemic. The 
treatment rate is defined based on individuals who had been 
diagnosed with dyslipidemia and had been taking lipid-lower-
ing drugs, and the control rate is defined as individuals who 
had been diagnosed with dyslipidemia and had LDL-C levels 
under 160 mg/dL, HDL-C levels over 40 mg/dL, and triglycer-
ide levels under 150 mg/dL.
Statistical analysis 
For prevalence calculations, we used the stratification variables 
and sampling weights designated by the Korean Centers for 
Disease Control and Prevention, which were based on the 
sample design of each survey year. Prevalence of dyslipidemia 
was estimated in subjects over 20 and 30, and ages were classi-
fied into 10-year increments. The standardized prevalence and 
the numbers of cases of dyslipidemia were calculated by sex- 
and age-specific 2005 Korean population. In the table, the co-
efficients of variation over 30% were expressed as separate no-
tations, and caution is required when interpreting correspond-
ing values. For the purpose of comparison, the prevalence, di-
agnosis, and treatment rates in 1998 and 2001 were also adjust-
ed to the age structure of the 2005 Korean population. Statisti-
cal analyses were performed using SAS version 9.2 (SAS Insti-
tute, Cary, NC, USA) and a P value of less than 0.05 was con-
sidered to be statistically significant. All statistical values gen-
erated in this research used the stratification variables used for 
sampling as well as weights, using the SAS survey procedure.
RESULTS 
The total numbers of subjects in this study were as follows: 
6,923 in KNHANES I (1998), 4,882 in KNHANES II (2001), 
and 5,323 in KNHANES III (2005). The mean ages of the par-
ticipants were 43.2, 45.8, and 43.4 years per survey year, respec-
tively. The mean ages of male participants were 42.6, 46.0, and 
42.6 years, respectively, and the mean ages of female partici-
pants were 43.7, 45.6, and 44.3 years.
Lipoprotein distribution 
The mean values of total cholesterol, HDL-C, LDL-C, and tri-
glycerides were presented for each survey year by gender ac-
cording to age groups of 20+, 30+, and so on in 10-year incre-
ments (Table 2). 
 Total cholesterol shows an increasing trend with age. Prior 
to age 50, the mean total cholesterol value in males is greater 
than in females. HDL-C decreases as age increases, but when 
examined by gender, is higher in females prior to age 50, al-
though it is similar in males and females older than 50. LDL-C 
in males did not deviate far from the gender mean value, where-
as as females age increases, the mean values showed an increas-
ing trend. The mean triglyceride level in males was the highest 
between the ages of 40 to 59, and highest in females between the 
ages of 50 to 69. When considering only KNHANES III (2005), 
the average total cholesterol and LDL-C levels were 2 to 3 mg/
dL lower in females than in males, and triglyceride levels were 
approximately 50 mg/dL lower in females. HDL-C was ap-
proximately 5 mg/dL higher in females than in males.
Prevalence of dyslipidemia
The prevalence of dyslipidemia in adults over age 20 was 32.4% 
in 1998 (males, 38.4%; females, 27.1%), and increased greatly 
to 42.6% in 2011 (males, 53.9%; females, 34.8%). The preva-
lence was 44.1% in 2005 (males, 54.5%; females, 34.0%), which 
was a slight increase over the 2001 survey. The age-standard-
ized prevalence in individuals older than 30 in 1998 was 35.8%, 
and 45.1% in 2001, which was a 9.3% increase within three 
years. In 2005, the age-standardized prevalence was 48.3%, 
which was 3.2% higher than in 2001. The prevalence of dyslip-
idemia was higher in males than in females (Table 3). A rapid 
increase in the prevalence of dyslipidemia in adults was ob-
served in all age (Fig. 1).
 The prevalence of hypercholesterolemia in adults over 20 
years of age was 8.6%, 8.2%, and 8.7%, respectively, by survey 
year. The prevalence slightly decreased from 1998 to 2001 and 
then increased again. The prevalence of hypo-HDL-cholester-
olemia gradually increased (20.4% in 1998, 27.6% in 2001, and 
33.4% in 2005), but the prevalence in males was higher than in 
females in all surveys. The prevalence of hyper-LDL-cholester-
olemia was 8.4% in 1998, 8.0% in 2001, and 5.9% in 2005. The 
prevalence of hyper-LDL-cholesterolemia was decreased from 
1998 to 2005. This pattern was similar for both males and fe-
males. The prevalence of hypertriglycemia was 9.8%, 18.3%, 
and 14.8%, respectively; the prevalence increased from 1998 
to 2001 and then began to decrease. In males, the prevalence 
of hypertriglycemia was 14.1%, 25.6%, and 20.8%, respective-
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ly, while those in females were 6.0%, 13.2%, and 8.9%. The re-
sults show that the prevalence was higher in males than in fe-
males (Table 3). 
 The prevalence of dyslipidemia and the number of cases es-
timated by 2005 population are presented in the Appendix 1 
to 5. When the results from the 2005 survey were examined, 
the prevalence of dyslipidemia in participants in their 20s was 
28.7% and surged to 41.8% in participants in their 30s. Between 
the ages of 50 and 70+, more than half of those surveyed were 
reported to have dyslipidemia. As age increased for both males 
and females, an increasing trend in dyslipidemia was seen. The 
prevalence of dyslipidemia in males between the ages of 20 
and 50 was nearly double the prevalence in females, although 
the prevalence was higher in females in the 60 to 70 age groups. 
In the age 70+ group, the prevalence in the male group was 
slightly higher than in female. The prevalence of hypercholes-
terolemia and hyper-LDL-cholesterolemia was higher in males 
until age 40 and higher in females after age 50. However, hy-
po-HDL-cholesterolemia and hypertriglycemia prevalence 
peaked in the 40 to 50 age range, after which a slight decreas-
ing trend could be seen. In nearly all age groups, the prevalence 
of hypo-HDL cholesterolemia and hypertriglycemia was slight-
ly higher in males (except females in their 60s). Among the 
components of dyslipidemia, the prevalence of hypo-HDL 
cholesterolemia was the highest, followed by hypertriglyce-
mia, and the prevalence of hyper-LDL cholesterolemia was the 
lowest, around 7 percent. 
 Age-standardized prevalence was 36.1% in 1998, 46.2% in 
2001, and 48.4% in 2005. Compared with the prevalence from 
1998, the prevalence in 2001 had increased by 1.47-fold (95% 
Table 3. Prevalence rates of dyslipidemia and lipid profiles in 
the KNHANES during 1998-2005 
KNHANES I (1998) 
Estimated prevalence 
(95% CI), %
KNHANES II (2001) 
Estimated prevalence 
(95% CI), %
KNHANES III (2005) 
Estimated prevalence 
(95% CI), %
Aged 20 yr and older
Dyslipidemia
Total 32.4 (31.0-33.8) 42.6 (40.7-44.6) 44.1 (42.3-45.9)
Men 38.4 (36.5-40.4) 53.9 (51.2-56.6) 54.5 (51.6-57.3)
Women 27.1 (25.3-28.9) 34.8 (32.3-37.2) 34.0 (31.7-36.2)
Hypercholesterolemia
Total 8.6 (7.7-9.4) 8.2 (7.3-9.0) 8.7 (7.8-9.6)
Men 7.8 (6.6-8.9) 7.6 (6.4-8.9) 8.5 (7.3-9.7)
Women 9.3 (8.1-10.4) 8.6 (7.3-9.8) 8.9 (7.6-10.2)
Hypo-HDL-cholesterolemia
Total 20.4 (19.2-21.6) 27.6 (25.7-29.6) 33.4 (31.7-35.0)
Men 25.5 (23.9-27.2) 37.1 (34.2-40.0) 43.5 (40.6-46.3)
Women 15.9 (14.5-17.3) 21.0 (19.0-23.0) 24.5 (21.7-25.4)
Hyper-LDL-cholesterolemia
Total 8.4 (7.5-9.2) 8.0 (7.1-9.0) 5.9 (5.1-6.7)
Men 7.6 (6.5-8.8) 7.9 (6.2-9.5) 5.6 (4.5-6.6)
Women 9.0 (7.9-10.1) 8.1 (6.9-9.4) 6.1 (5.0-7.2)
Hypertriglycemia
Total 9.8 (8.8-10.8) 18.3 (16.9-19.6) 14.8 (13.4-16.1)
Men 14.1 (12.7-15.5) 25.6 (23.4-27.7) 20.8 (18.6-23.1)
Women 6.0 (5.0-7.0) 13.2 (11.6-14.7) 8.9 (7.7-10.1)
Aged 30 yr and older
Dyslipidemia
Total 35.8 (34.2-37.4) 45.1 (43.1-47.2) 48.3 (46.6-50.1)
Men 41.8 (39.6-44.0) 56.0 (53.2-58.8) 58.9 (56.2-61.5)
Women 30.5 (28.4-32.6) 37.5 (34.8-40.3) 38.2 (35.8-40.7)
Hypercholesterolemia
Total 9.9 (8.8-10.9) 9.0 (8.0-10.0) 10.6 (9.6-11.7)
Men 8.9 (7.5-10.2) 8.0 (6.5-9.4) 10.3 (8.9-11.7)
Women 10.8 (9.3-12.2) 9.7 (8.3-11.1) 10.9 (9.4-12.5)
Hypo-HDL-cholesterolemia
Total 22.1 (20.8-23.5) 28.7 (26.6-30.7) 36.3 (34.7-37.9)
Men 27.2 (25.3-29.1) 38.0 (34.9-41.0) 47.2 (44.4-50.0)
Women 17.6 (16.1-19.2) 22.2 (20.0-24.4) 25.8 (23.8-27.8)
Hyper-LDL-cholesterolemia
Total 9.8 (8.7-10.9) 8.9 (7.8-10.0) 7.1 (6.2-8.0)
Men 8.8 (7.4-10.1) 8.4 (6.5-10.3) 6.7 (5.5-7.9)
Women 10.7 (9.3-12.1) 9.2 (1.8-10.7) 7.4 (6.1-8.8)
Hypertriglycemia
Total 11.0 (9.8-12.1) 19.6 (18.1-21.1) 16.7 (15.3-18.2)
Men 15.7 (14.0-17.4) 27.0 (24.7-29.3) 23.3 (20.9-25.7)
Women 6.7 (5.5-7.9) 14.4 (12.7-16.2) 10.4 (8.9-11.8)
KNHANES, Korea National Health and Nutrition Examination Sur-
vey; CI, confidence interval; HDL, high density lipoprotein; LDL, low 
density lipoprotein.
Fig. 1. Age-specific prevalence rates of dyslipidemia in the Korea 
National Health and Nutrition Examination Survey (KNHANES) 
during 1998-2005. 
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confidence interval [CI], 1.35 to 1.59), and in 2005 it had in-
creased by 1.61-fold (95% CI, 1.49 to 1.75). Overtime, the 
prevalence of dyslipidemia tended to increase in both males 
and females, but the prevalence rate in males increased more 
quickly (Table 4).
 In the 2005 survey, awareness, physician diagnosis, treat-
ment rate, and control rate in individuals over age 30 diag-
nosed with dyslipidemia were examined. The awareness rate, 
physician diagnosis rate, and treatment rate were slightly high-
er in females (Table 5). The control rate of dyslipidemia, when 
examined according to the presence of accompanying risk fac-
tors, was 56.3% in the 0 to 1 risk factors group, and 13.1% in 
the group with two or more risk factors (data not shown).
DISCUSSION
In this study, the lipoprotein distribution and prevalence of 
dyslipidemia were estimated based on data from KNHANES 
conducted in 1998, 2001, and 2005. The yearly changes in the 
trends of prevalence were also analyzed. The prevalence of 
dyslipidemia in participants over age 20 was 32.4% in 1998, 
42.6% in 2001, and 44.1% in 2005. The results also showed 
that the prevalence was higher in males than in females. The 
prevalence of dyslipidemia in males was 38.4%, 53.9%, and 
54.5%, respectively, and 27.1%, 34.8%, and 34.0% in females, 
respectively.
 Dyslipidemia is the most manageable risk factor of athero-
sclerotic cardiovascular disease. The relationship between in-
creased cholesterol and mortality rate due to coronary heart 
disease has been reported in numerous epidemiological stud-
ies [11,12]. A previous study reported that both total choles-
terol and LDL-C increase total mortality rates [13]. According 
to a meta-analysis of several epidemiological studies, when 
HDL-C increased by 1.0 mg/dL, the occurrence of coronary 
heart disease decreased by 2% to 3% [14]. 
 In the KNHANES data analysis, hypo-HDL-cholesterolemia 
had the highest prevalence rate, followed by hypertriglycemia. 
The high HDL-C and triglyceride levels are thought to be 
caused by Korea’s carbohydrate-centered diet [15] and are also 
correlated with a recent rapidly increased prevalence of obesi-
ty and type 2 diabetes. In particular, high triglyceride levels in 
diabetic patients are very common. In populations with high 
triglyceride levels, the incidence of cardiovascular disease is 
over two times higher compared to that in populations with 
normal levels [16]. In the KNHANES, the prevalence of hy-
pertriglycemia in the normal glucose group was 6.7% and the 
prevalence of hypo-HDL-cholesterolemia was 30.7%, whereas 
in the impaired fasting glucose group, they were 14.9% and 
42.4%, respectively, and in the diabetes group, they were 20.1% 
and 46.8% (P<0.0001).
 Based on the type of dyslipidemia, the risk of coronary ar-
Table 4. Age-standardized prevalence rates of dyslipidemia in 
the KNHANES during 1998-2005 (aged 30 years or older)
Dyslipidemia
Crude 
prevalence 
rates, %
Age-standard-
ized preva-
lence rates, %
OR (95% CI)
Total
KNHANES I (1998) 35.8 36.1 1.00
KNHANES II (2001) 45.1 46.2 1.47 (1.35-1.59)
KNHANES III (2005) 48.3 48.4 1.61 (1.49-1.75)
Men
KNHANES I (1998) 41.8 41.7 1.00 
KNHANES II (2001) 56.0 55.5 1.73 (1.53-1.95)
KNHANES III (2005) 58.9 58.8 1.97 (1.74-2.22)
Women
KNHANES I (1998) 30.5 30.8 1.00 
KNHANES II (2001) 37.5 37.3 1.28 (1.14-1.44)
KNHANES III (2005) 38.2 38.3 1.40 (1.25-1.56)
KNHANES, Korea National Health and Nutrition Examination Sur-
vey; OR, odds ratio; CI, confidence interval.
Table 5. Awareness, diagnosis, and control rates of dyslipid-
emia in the KNHANES, 2005 (aged 30 years or older)
Crude rate, % Age-standardized rate, %
Total Men Women Total Men Women
Awareness ratea 9.5 8.1 11.4 8.9 8.0 9.8 
Physician diag-
nosis rateb
9.4 8.1 11.4 8.8 8.0 9.7 
Treatment ratec 5.2 4.4 6.4 4.8 4.4 5.2
Control rated 33.2 28.4 38.1 24.7 23.3 26.0
Control ratee 37.4 32.5 42.2 27.2 25.7 28.5
KNHANES, Korea National Health and Nutrition Examination Survey.
aProportion of patients with awareness of the disease of all patients 
with dyslipidemia, bProportion of patients with previous diagnosis of 
all patients with dyslipidemia, cProportion of patients using lipid-low-
ering medication of all patients with dyslipidemia, dProportion of pa-
tients who achieved the treatment goal of all patients with dyslipid-
emia using lipid-lowering medication, eProportion of patients who 
achieved the treatment goal of all patients with hyper-LDL-cholester-
olemia using lipid-lowering medication. 
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tery disease differs between genders. LDL-C is the most indic-
ative predicting factor in males, while HDL-C is the most in-
dicative factor in females, while triglycerides are the second 
most indicative in both sexes [17,18]. The mean cholesterol 
concentration in females was lower than that in males in our 
analysis. However, there were more females with hypercholes-
terolemia with cholesterol concentrations over 240 mg/dL. One 
possible reason is that pre-menopausal females have lower lip-
id levels than males due to hormonal effects, but after meno-
pause lipid levels rapidly increase and become similar or high-
er than that of males [19,20]. In the KNHANES III survey 
(2005), the prevalence of dyslipidemia increased with age. Af-
ter the prevalence of dyslipidemia in males peaks in their 50s 
and in women in their 60s, it decreases slightly, and we ob-
served that the onset of dyslipidemia occurs 10 years later in 
women than in men. Our analysis showed that more than half 
of the individuals aged 50+ had dyslipidemia. Yet, the aware-
ness rate of dyslipidemia and the treatment rates are still low, 
and treatment is limited to hyper-LDL-cholesterolemia [21,22]. 
In this study, the prevalence of dyslipidemia continuously in-
creases, especially first appearing in younger males in 20s and 
30s. In order to prevent cardiovascular disease, it is necessary 
to educate, screen, and aggressively treat dyslipidemia in young-
er age subjects. 
 The mortality rate of cardiovascular disease in Korea is still 
lower than that in the USA. When the actual distribution of li-
poproteins by age and gender were compared with the United 
States, the mean total cholesterol levels of Korean above age 20 
were lower. The LDL-C levels of Korean were also lower. How-
ever, triglyceride levels in Korean participants were higher than 
that of participants from the United States. HDL-C levels were 
lower in Koreans than in Americans. Especially, HDL-C and 
triglyceride levels in Korean females were much worse than in 
females from the United States [23]. In the USA, between 1960 
and 2002, total cholesterol and LDL-C levels had continuously 
decreased due to ongoing efforts, and cardiovascular disease 
had decreased. However, triglyceride levels increased as a re-
sult of continuously increase in prevalence of diabetes and 
obesity [24]. Since Koreans have significantly higher triglycer-
ide levels than Americans, proper management is urgent. In 
the USA, the prevalence of hypercholesterolemia (≥260 mg/
dL) was 34.2% in males and 41.6% in females [23]. In recent 
years, total cholesterol decreased in the USA but still higher 
than in Koreans. 
 In Japan, total cholesterol levels have increased by 5 mg/dL 
in the last 10 years. The total cholesterol levels in Japanese were 
10 to 20 mg/dL higher than in Koreans in all age groups. How-
ever, LDL-C levels were similar, HDL-C was 14 mg/dL higher 
and triglyceride levels were 20 mg/dL lower in Japanese than 
in Koreans [25]. Since the definitions of hypercholesterolemia, 
hypertriglycemia, and dyslipidemia are not identical, care is 
needed when interpreting these results. 
 Although it is based on a national representative survey, this 
study also has several limitations. First, this is a cross-sectional 
analysis and cannot investigate the factors affecting prevalence 
and management of dyslipidemia. Second, dyslipidemia was 
defined based on blood tests in 1998 and 2001, but was defined 
through an integration of blood tests, physician diagnosis and 
treatment in 2005. Differences in the definitions of dyslipid-
emia might affect the prevalence estimation and make direct 
comparisons difficult. Third, the health interview and the health 
behavior surveys were not consistent over time, and the treat-
ment and control rates were estimated only in the 2005 survey. 
 In conclusion, by analyzing datasets from the KNHANES 
conducted in 1998, 2001, and 2005, we observed an increase 
in the prevalence of dyslipidemia in Korea. In 2005, the preva-
lence approached nearly 50% of the adult population over age 
30. The primary forms of dyslipidemia were hypo-HDL-cho-
lesterolemia and hypertriglycemia. These findings suggest that 
more intense efforts are required to prevent from and control 
dyslipidemia in Korean adults.
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Appendix 1. Prevalence of dyslipidemia in the KNHANES during 1998-2005 by age category
KNHANES I (1998) KNHANES II (2001) KNHANES III (2005)
No.a % 95% CI No.a % 95% CI No.a % 95% CI
Total
20-29 1,684,205 20.1 17.5-22.7 2,378,898 29.2 25.4-33.1 2,177,374 28.7 24.4-33.0
30-39 2,377,148 27.9 25.7-30.0 3,055,416 35.7 32.3-39.0 3,567,384 41.8 38.6-45.0
40-49 2,171,051 34.8 32.0-37.7 2,902,380 39.7 36.4-43.1 3,907,372 47.6 44.4-50.7
50-59 1,782,069 42.4 39.2-45.5 2,261,382 51.0 46.5-55.5 2,861,546 55.7 51.8-59.5
60-69 1,355,973 45.9 41.7-50.1 1,918,785 57.7 52.4-63.0 1,920,000 53.2 49.4-56.9
70+ 717,269 39.0 33.8-44.2 1,176,747 55.7 50.4-61.0 1,382,328 51.5 46.7-56.3
Men
20-29 1,108,218 25.8 22.0-29.5 1,792,838 42.7 36.1-49.3 1,537,918 39.3 31.7-46.8
30-39 1,748,042 40.1 36.2-44.0 2,285,531 52.2 47.3-57.1 2,500,5704 57.2 52.3-62.1
40-49 1,407,198 44.2 40.0-48.3 2,082,858 56.1 51.3-61.0 2,558,861 61.2 56.5-66.0
50-59 931,926 44.8 40.2-49.4 1,212,109 54.8 48.3-61.3 1,658,109 64.5 58.7-70.4
60-69 549,767 41.9 36.2-47.6 893,545 59.0 51.1-67.0 862,391 51.6 45.3-58.0
70+ 194,794 30.3 23.8-36.8 474,844 63.9 55.1-72.7 520,163 53.3 45.0-61.6
Women
20-29 628,892 15.4 12.1-18.6 781,749 19.8 15.8-23.8 650,190 17.7 13.8-21.6
30-39 690,732 16.6 14.1-19.2 999,062 23.9 20.2-27.7 1,053,183 25.3 21.8-28.8
40-49 772,902 25.3 21.5-29.0 1,050,622 29.2 24.9-33.5 1,349,252 33.5 29.7-37.3
50-59 849,120 40.0 35.8-44.3 1,073,325 48.3 41.7-55.0 1,203,788 46.9 41.3-52.5
60-69 807,912 49.2 43.9-54.5 1,025,008 56.6 50.1-63.1 1,056,058 54.5 49.2-59.8
70+ 520,377 43.5 36.7-50.3 690,251 50.4 43.1-57.8 860,941 50.4 43.6-57.1
KNHANES, Korea National Health and Nutrition Examination Survey; CI, confidence interval.
aThe number of cases of prevalent dyslipidemia is a 2005 population estimate.
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Appendix 2. Prevalence of hypercholesterolemia in the KNHANES during 1998-2005 by age category
KNHANES I (1998) KNHANES II (2001) KNHANES III (2005)
No.a % 95% CI No.a % 95% CI No.a % 95% CI
Total
20-29 318,407 3.8 2.7-4.8 309,583 3.8 2.3-5.2 136,560 1.8b 0.4-3.1
30-39 400,452 4.7 3.6-5.8 445,047 5.2 3.8-6.6 435,255 5.1 3.7-6.5
40-49 530,285 8.5 6.7-10.3 467,890 6.4 4.9-8.0 820,876 10.0 8.3-11.6
50-59 664,073 15.8 13.4-18.3 514,354 11.6 9.3-13.9 821,988 16.0 13.3-18.7
60-69 434,266 14.7 11.9-17.4 548,699 16.5 12.7-20.3 617,143 17.1 13.7-20.4
70+ 246,446 13.4 10.2-16.6 209,152 9.9 6.5-13.2 308,675 11.5 8.0-15.0
Men
20-29 154,635 3.6 2.1-5.1 243,524 5.8 2.8-8.9 86,092 2.2 0.0-4.8
30-39 283,348 6.5 4.6-8.4 262,705 6.0 3.8-8.1 340,987 7.8 5.4-10.3
40-49 318,371 10.0 7.2-12.7 315,585 8.5 5.9-11.0 531,005 12.7 10.1-15.3
50-59 260,024 12.5 9.5-15.6 192,433 8.7 5.2-12.2 318,768 12.4 8.6-16.2
60-69 127,273 9.7 6.4-13.0 159,021 10.5 5.2-15.8 182,172 10.9 7.4-14.4
70+ 22,501 3.5b 1.1-6.0 46,816 6.3b 2.2-10.5 48,796 5.0b 1.3-8.7
Women
20-29 159,265 3.9 2.5-5.3 90,809 2.3 1.0-3.7 44,081 1.2b 0.2-2.2
30-39 128,992 3.1 1.9-4.3 196,468 4.7 2.7-6.6 95,744 2.3 1.2-3.4
40-49 213,846 7.0 4.9-9.1 183,499 5.1 3.2-7.0 289,989 7.2 4.8-9.6
50-59 403,332 19.0 15.3-22.7 302,220 13.6 10.4-17.0 503,076 19.6 15.2-23.9
60-69 305,430 18.6 14.4-22.9 387,728 21.4 16.1-26.6 434,050 22.4 17.5-27.3
70+ 221,310 18.5 13.8-23.2 165,715 12.1 7.4-16.8 261,357 15.3 10.5-20.2
KNHANES, Korea National Health and Nutrition Examination Survey; CI, confidence interval.
aThe number of cases of prevalent hypercholesterolemia is a 2005 population estimate, bCoefficient of variation is over than 30%.
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Appendix 3. Prevalence of hypo-HDL-cholesterolemia in the KNHANES during 1998-2005 by age category
KNHANES I (1998) KNHANES II (2001) KNHANES III (2005)
No.a % 95% CI No.a % 95% CI No.a % 95% CI
Total
20-29 1,189,837 14.2 11.9-16.4 1,776,027 21.8 18.3-25.3 1,729,761 22.8 19.0-26.6
30-39 1,721,089 20.2 18.1-22.3 2,105,413 24.6 21.4-27.7 2,961,441 34.7 31.6-37.8
40-49 1,397,458 22.4 19.8-25.0 1,878,870 25.7 22.8-28.5 2,856,650 34.8 31.6-38.1
50-59 924,658 22.0 19.1-24.9 1,299,186 29.3 25.2-33.4 1,998,458 38.9 34.9-42.8
60-69 738,548 25.0 21.6-28.4 1,160,582 34.9 29.7-40.2 1,393,082 38.6 34.5-42.6
70+ 456,109 24.8 20.5-29.1 794,357 37.6 32.1-43.2 1,019,970 38.0 33.4-42.5
Men
20-29 824,720 19.2 15.9-22.6 1,360,373 32.4 26.1-38.6 1,189,637 30.4 23.5-37.3
30-39 1,251,092 28.7 25.0-32.3 1,571,850 35.9 30.8-41.0 2,098,383 48.0 43.2-52.9
40-49 897,805 28.2 24.4-32.0 1,347,732 36.3 31.8-40.8 1,960,957 46.9 41.8-52.0
50-59 526,289 25.3 20.8-29.7 783,005 35.4 29.3-41.5 1,295,639 50.4 44.3-56.6
60-69 326,711 24.9 20.1-29.7 608,822 40.2 31.9-48.6 706,960 42.3 35.9-48.8
70+ 163,292 25.4 19.7-31.2 372,296 50.1 40.5-59.7 432,330 44.3 35.4-53.3
Women
20-29 404,288 9.9 7.3-12.6 564,597 14.3 10.9-17.8 543,662 14.8 11.2-18.4
30-39 515,969 12.4 10.2-14.6 693,909 16.6 13.5-19.7 857,532 20.6 17.2-24.1
40-49 501,011 16.4 13.4-19.5 676,428 18.8 15.3-22.4 902,187 22.4 19.0-25.8
50-59 254,736 12.0 15.8-21.9 555,551 25.0 19.8-30.2 703,279 27.4 21.9-32.8
60-69 412,167 25.1 20.8-29.3 554,156 30.6 24.6-36.7 684,016 35.3 30.2-40.5
70+ 293,086 24.5 19.0-30.0 406,755 29.7 22.7-35.7 584,210 34.2 28.5-39.9
HDL, high density lipoprotein; KNHANES, Korea National Health and Nutrition Examination Survey; CI, confidence interval.
aThe number of cases of prevalent hypo-HDL cholesterolemia is a 2005 population estimate.
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Appendix 4. Prevalence of hyper-LDL cholesterolemia in the KNHANES during 1998-2005 by age category
KNHANES I (1998) KNHANES II (2001) KNHANES III (2005)
No.a % 95% CI No.a % 95% CI No.a % 95% CI
Total
20-29 259,753 3.1 2.1-4.2 276,995 3.4 2.1-4.7 113,800 1.5b 0.1-3.0
30-39 383,411 4.5 3.4-5.7 402,254 4.7 3.5-5.9 349,911 4.1 2.8-5.5
40-49 486,615 7.8 6.1-9.5 453,268 6.2 4.7-7.7 591,031 7.2 5.5-8.9
50-59 613,637 14.6 12.2-17.0 585,299 13.2 10.4-15.9 493,193 9.6 7.6-11.7
60-69 487,441 16.5 13.4-19.6 472,214 14.2 9.8-18.6 339,248 9.4 7.1-11.7
70+ 281,390 15.3 11.8-18.8 249,293 11.8 8.2-15.3 230,835 8.6 5.8-11.4
Men
20-29 141,749 3.3 1.9-4.8 214,133 5.1 2.6-7.5 74,352 1.9b 0.0-4.5
30-39 296,426 6.8 4.7-8.9 236,434 5.4 3.7-7.2 275,413 6.3 3.9-8.6
40-49 305,636 9.6 6.9-12.4 308,159 8.3 5.5-11.2 351,216 8.4 5.8-11.1
50-59 224,661 10.8 8.1-13.6 232,247 10.5 6.6-14.4 151,672 5.9 3.3-8.5
60-69 143,018 10.9 7.4-14.3 175,680 11.6b 3.7-19.4 96,935 5.8 2.9-8.8
70+ 28,930 4.5b 1.5-7.4 54,990 7.4 3.1-11.6 46,844 4.8b 1.9-7.7
Women
20-29 122,511 3.0 1.7-4.3 86,861 2.2b 0.9-3.5 44,081 1.2b 0.4-0.9
30-39 99,865 2.4 1.3-4.5 175,567 4.2 2.4-5.9 79,093 1.9 0.8-3.1
40-49 183,297 6.0 4.0-8.0 172,705 4.8 3.1-6.6 237,630 5.9 3.7-8.1
50-59 386,350 18.2 14.5-21.8 333,331 15.0 10.8-19.3 336,239 13.1 9.7-16.6
60-69 343,198 20.9 16.2-25.7 293,377 16.2 11.4-21.1 240,277 12.4 8.7-16.1
70+ 248,824 20.8 15.9-25.8 198,584 14.5 9.2-19.8 184,487 10.8 6.6-15.0
LDL, low density lipoprotein; KNHANES, Korea National Health and Nutrition Examination Survey; CI, confidence interval.
aThe number of cases of prevalent hyper-LDL cholesterolemia is a 2005 population estimate, bCoefficient of variation is over than 30%.
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Appendix 5. Prevalence of hypertriglycemia in the KNHANES during 1998-2005 by age category
KNHANES I (1998) KNHANES II (2001) KNHANES III (2005)
No.a % 95% CI No.a % 95% CI No.a % 95% CI
Total
20-29 477,610 5.7 4.3-7.0 896,160 11.0 8.4-13.6 591,760 7.8 4.9-10.7
30-39 673,099 7.9 6.6-9.2 1,181,085 13.8 11.5-16.1 1,075,336 12.6 10.2-15.1
40-49 748,638 12.0 10.1-13.9 1,352,494 18.5 16.0-21.1 1,526,830 18.6 16.1-21.1
50-59 575,810 13.7 11.2-16.2 997,668 22.5 18.7-26.3 1,083,997 21.1 17.9-24.3
60-69 422,449 14.3 11.2-17.3 884,570 26.6 22.7-31.4 627,970 17.4 14.5-20.4
70+ 148,971 8.1 5.3-10.8 473,234 22.4 17.4-27.4 386,515 14.4 10.6-18.2
Men
20-29 347,929 8.1 5.7-10.5 747,366 17.8 12.9-22.7 481,333 12.3 7.2-17.3
30-39 592,852 13.6 11.1-16.1 1,085,846 24.8 21.0-28.6 896,185 20.5 16.1-24.8
40-49 576,251 18.1 15.2-21.1 1,072,987 28.9 24.3-33.4 1,174,902 28.1 23.7-32.6
50-59 388,996 18.7 14.9-22.5 621,538 28.1 22.7-33.6 691,522 26.9 22.0-31.9
60-69 194,190 14.8 10.6-19.0 408,910 27.0 21.3-33.5 317,547 19.0 14.4-23.5
70+ 51,431 8.0 4.8-11.2 188,006 25.3 16.2-34.5 126,869 13.0 7.4-18.6
Women
20-29 147,014 3.6 2.1-5.1 244,790 6.2 3.9-8.6 113,875 3.1 1.3-4.9
30-39 112,348 2.7 1.7-3.7 250,811 6.0 4.0-8.0 178,999 4.3 2.9-5.8
40-49 174,132 5.7 3.7-7.8 428,164 11.9 8.9-14.9 354,430 8.8 6.3-11.3
50-59 188,929 8.9 6.4-11.5 411,108 18.5 14.0-23.0 392,707 15.3 11.3-19.4
60-69 226,610 13.8 9.9-17.8 469,041 25.9 20.9-30.9 313,911 16.2 12.3-20.0
70+ 96,898 8.1 4.7-11.4 280,757 20.5 15.0-25.9 259,649 15.2 10.5-20.0
KNHANES, Korea National Health and Nutrition Examination Survey; CI, confidence interval.
aThe number of cases of prevalent hypertriglycemia is a 2005 population estimate.
